US pharmaceutical company Novavax has announced the sale of its manufacturing facility in the Czech Republic to Danish firm Novo Nordisk for USD 200 million.

Novavax's Czech plant produces an important component of the Nuvaxovid covid vaccine. It was previously used by Baxter to produce swine flu vaccines. The transaction involves the transfer of assets, including a state-of-the-art recombinant protein production facility, and all related and necessary infrastructure.

Novo Nordisk, founded in 1923, is a world leader in the treatment of diabetes and other chronic diseases such as obesity, rare blood diseases and endocrine disorders. The company operates in more than 80 countries, employs more than 64,000 people and sells its products in 170 countries. Novo Nordisk has become the most valuable company in Europe thanks to the success of its weight loss drug Wegovy.